PMID

Data

Article Title

Organization

PD 176252--the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist.

Cambridge University Forvie Site

 

Design and synthesis of a targeted set of aromatic amino acid derivatives for identification of new lead compounds

TBA

 

PD 165929 the first high affinity non-peptide neuromedin-B (NMB) receptor selective antagonist

TBA

Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity

TBA

Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.

Merck Research Laboratories

Discovery of substituted biphenyl imidazoles as potent, bioavailable bombesin receptor subtype-3 agonists.

Merck Research Laboratories

Discovery and optimization of a novel Neuromedin B receptor antagonist.

Amgen

Discovery of small molecule agonists for the bombesin receptor subtype 3 (BRS-3) based on an omeprazole lead.

Glaxosmithkline

Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study.

National Center For Scientific Research Demokritos

Identification and optimization of novel partial agonists of neuromedin B receptor using parallel synthesis.

Tularik

Design of selective peptidomimetic agonists for the human orphan receptor BRS-3.

Technische UniversitäT MüNchen

SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.

Sanofi-Synthelabo Recherche

Development of bombesin analogs with conformationally restricted amino acid substitutions with enhanced selectivity for the orphan receptor human bombesin receptor subtype 3.

National Institutes of Health

Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).

National Institute of Diabetes and Digestive and Kidney Diseases